What's Happening?
A recent study has found that semaglutide, a GLP-1 drug commonly used for weight loss, may also slow biological aging. Conducted on 108 adults with HIV-associated lipohypertrophy, the study used epigenetic clocks to measure biological aging. Participants
receiving semaglutide injections showed a 9% slower aging rate compared to those on a placebo. The drug appeared to counteract accelerated aging effects linked to chronic inflammation and immune system activation, common in people with HIV. These findings suggest that semaglutide could have broader implications beyond weight management, potentially benefiting the general population.
Why It's Important?
The study's implications extend beyond its initial focus group, suggesting that semaglutide could play a role in slowing biological aging for a wider audience. This could revolutionize how aging-related health issues are approached, offering a new tool for managing age-related diseases and improving longevity. The potential to slow biological aging could lead to reduced healthcare costs and improved quality of life for aging populations. As the drug is already widely prescribed for weight loss, these findings could enhance its appeal and application in medical practice.
